Phagenesis

Founded in 2007, Phagenesis is committed to scientific and clinical excellence in the development of novel therapies to treat patients suffering from neurogenic dysphagia.

The foundational science and clinical evidence for the Pharyngeal Electrical Stimulation used in Phagenyx has been peer reviewed and published at the highest level.

First to map the swallow motor cortex in health & disease.
First to show that dysphagia recovery is due to functional reorganization of the swallow motor cortex.
First to show that long-term reorganization of the cortex can be driven by short term sensory stimulation.
First to show that sensory stimulation driven reorganization results in functional swallow recovery.
First in a multicenter RCT to show that Phagenyx® responders had a statistically significant shorter length of stay versus non-responders.
First to demonstrate in a multicenter registry of real-world data clinically significant improvements in CNS, nonCNS, mechanically ventilated, and non-ventilated patients using a range of dysphagia outcome measures.

Leadership

CHAD HOSKINS

Chief Executive Officer

CONOR MULROONEY

Co-Founder & Chief Operating Officer

ANDRE NEL

Chief Financial Officer

SHAHEEN HAMDY

Co-Founder & Chief Scientific Officer

BORIS DEUTSCHMANN

Director European Sales

SCOTT GRANT

VP US Therapy Development

ANIL KENI

VP Global Marketing

CARI MANYPENNY

Head of Global Education

STEPHEN HALSTEAD

Head of QA/RA

KATE ECKLUND

VP Clinical Affairs

Board of Directors

OERN STUGE

Chairperson, Director
Chairperson Orsco Lifesciences AG

FRED EDENIUS

Director
Founder / Director Scientific Venture Partners

MICHEL GARDET

Director
Representing Nestle Health Sciences

DREW BURDON

Director
Partner EQT Lifesciences

MICHAEL SJÖSTRÖM

Director
Co-founder / Partner Sectoral Asset Management

MARK WYATT

Director
Investment Director Northern Gritstone

CHAD HOSKINS

Director
CEO Phagenesis

Kate Ecklund

VP Clinical Affairs
An innovative, solution-driven leader with over 15 years of experience in designing and leading high-impact global trials that bring novel therapies to market and improve patient lives. Prior experience at Medtronic, Surmodics, Mainstay Medical, and Alucent Biomedical and across multiple therapy areas.

Stephen Halstead

Head of QA/RA
Experienced multinational medical device Quality professional with a steadfast commitment to continuous improvement of global Quality Management Systems and processes. A track record of scaling international operations and businesses to meet and exceed critical growth objectives.

Cari Manypenny

Head of Global Education
Dedicated medical speech-language pathologist and educator. Extensive experience in patient care, clinical education, and research. Committed to enhancing patient care and improving the lives of people with dysphagia.

Anil Keni

VP Global Marketing
Marketing leader with strong background in engineering and sales. Years of commercialization experience at highly reputable companies (Edwards, Abbott, STORZ). Committed to serving patients with a start-up work ethic and a ‘can-do’ mindset.

Scott Grant

VP US Therapy Development
Market development professional with decades of commercial success in emerging and established companies (Guidant, Abbott). Driven to bring innovation safely and effectively to market.

Boris Deutschmann

Director European Sales
Tech enthusiast and entrepreneur passionate about transforming care for underserved patients. Proven Sales Leader with a track record of driving success in Europe’s medtech market, launching cutting-edge solutions for startups and industry giants like Mainstay Medical, Nevro, and Abbott (St. Jude Medical).

Shaheen Hamdy

Co-Founder & Chief Scientific Officer
Professor of Neurogastroenterology and inventor. Focused on advancing the neuroscience of swallowing control through research on neuroplasticity and functional recovery following brain injury. One of the highest cited academics in the field of dysphagia.

Andre Nel

Chief Financial Officer
Dynamic CFO with over 20 years of international experience, specializing in global scaling, financial leadership, and sustainable growth, with expertise in IPO readiness, market expansion, and risk management.

CONOR MULROONEY

Co-Founder & Chief Operating Officer
Operations leader and inventor. Molecular biology, process automation and technical management expertise. Lead inventor on 50+ patents. Innovation driven with a focus on real-world solutions.

CHAD HOSKINS

Chief Executive Officer
An accomplished executive leader with over two decades of experience launching cutting-edge medical technologies. Prior experience includes leadership roles with Axon Therapies, Outset Medical, Abbott, Thoratec and McKinsey & Co.